Larvol Delta - Captor-Therapeutics-Nominates-the-Molecular-Glue-CPT6281-as-Drug-Candidate-to-Enter-CTAINDEnabling-Studies-for-the-Treatment-of-Hepatocellular-Carcinoma

CPT-6281 - Captor Therap

https://www.globenewswire.com/news-release/2022/08/10/2495459/0/en/Captor-Therapeutics-Nominates-the-Molecular-Glue-CPT-6281-as-Drug-Candidate-to-Enter-CTA-IND-Enabling-Studies-for-the-Treatment-of-Hepatocellular-Carcinoma.html

Aug 10, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next